. Author manuscript; available in PMC: 2009 Jan 1.

Published in final edited form as: Cancer Chemother Pharmacol. 2007 Mar 29;61(1):133–144. doi: 10.1007/s00280-007-0458-z

Table 1.

Pharmacokinetics of control rapamycin, rapamycin in PEG-b-PCL, and rapamycin in PEG-b-PCL + α-tocopherol in blood after IV administration in rats (mean ± SEM, n = 4) between both formulations

Pharmacokinetic parameter	Rapamycin control	Rapamycin in PEG-b-PCL	Rapamycin in PEG-b-PCL + α-tocopherol
AUC_inf (μg h/ml)	7.584 ± 0.887	8.556 ± 0.248	11.929 ± 0.412^a,^b
AUC_0-48h (μg h/ml)	7.294 ± 0.992	8.378 ± 0.204	11.751 ± 0.399^a,^b
Vd_β (l/kg)	23.993 ± 3.466	26.696 ± 1.302	17.745 ± 1.272^b
CL_renal (l/h kg)	0.053 ± 0.012	0.022 ± 0.002^a	0.012 ± 0.003^a,^b
CL_hepatic (l/h kg)	1.284 ± 0.012	1.150 ± 0.035	0.828 ± 0.027^a,^b
CL_tot (l/h kg)	1.337 ± 0.156	1.172 ± 0.034	0.840 ± 0.028^a,^b
KE (h⁻¹)	0.056 ± 0.001	0.044 ± 0.002^a	0.048 ± 0.03
t_1/2 (h) blood	12.396 ± 0.346	15.820 ± 0.843	14.626 ± 0.812
t_1/2 (h) urine	10.296 ± 0.014	10.647 ± 0.061^a	21.393 ± 0.026^a,^b
MRT (h)	8.770 ± 3.120	4.833 ± 0.780	4.304 ± 0.355
Extraction ratio (ER)	0.399 ± 0.045	0.357 ± 0.011	0.257 ± 0.008^a,^b
Estimated bioavailability (%)	60.123 ± 3.169	64.293 ± 1.092	74.297 ± 0.836^a,^b

Denotes statistical significant difference (P < 0.05) between control and formulation

Denotes statistical significant difference (P < 0.05)